TABLE 2.

177Lu-PSMA Therapy

ParameterData
Patients133
Number of 177Lu-PSMA infusions
 117 (13)
 233 (25)
 316 (12)
 431 (23)
 513 (10)
 614 (11)
 >69 (7)
Duration of 177Lu-PSMA therapy (mo)4.4 (0.0–57.1)
Time from last 223Ra injection to first 177Lu-PSMA dose (mo)*12.0 (0.7–74.3)
Time from mCRPC diagnosis to first 177Lu-PSMA dose (mo)37.8 (7.4–161.5)
Treatment delay/interruption/cessation51 (38)
 Due to disease progression23 (17)
 Due to AE13 (10)
  • * Last injection from first 223Ra treatment cycle in case of multiple cycles.

  • Patients could have >1 delay and >1 reason for different delays.

  • Qualitative data are number and percentage; continuous data are median and range. Patients switched to another carrier molecule are reported under first carrier molecule.